Journal
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
Volume 9, Issue 8, Pages 1296-1301Publisher
WILEY
DOI: 10.1002/acn3.51609
Keywords
-
Categories
Funding
- Swedish Federal Government (LUA/ALF) [ALFGBG-722081]
- Swedish Society of the Neurologically Disabled
- Research Foundation of the Multiple Sclerosis Society of Gothenburg
- Edit Jacobson Foundation
- ProjektDEAL
Ask authors/readers for more resources
SARS-COV-2 infection can result in MOGAD, but there is no evidence of cross-reactive immune response between the virus and MOG.
SARS-COV-2 frequently cause neurological disorders and is sometimes associated with onset of autoimmune diseases affecting the nervous system. Over recent years, a rare but distinct diagnosis designated myelin oligodendrocyte glycoprotein-associated disorder (MOGAD) has been recognized in patients with attacks of optic neuritis, myelitis, or encephalomyelitis and increased levels of anti-MOG antibodies. The cause of MOGAD is unknown. However, there have been reports of single cases of MOGAD in patients with Covid-19 infection. We report a series of SARS-CoV-2 positive patients that developed MOGAD, but a homology search did not support a cross-reactive immune response to SARS-CoV-2 spike-protein and MOG.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available